HPV vaccination's second act: promotion, competition, and compulsion.
Developments regarding human papillomavirus (HPV) vaccines will transform HPV vaccination in the United States while simultaneously raising several new policy and ethical concerns. Policymakers, vaccine manufacturers, and the public health community must now respond to the presence of competing vaccines that are similar but distinct, particularly with respect to genital wart prevention and the benefits of vaccinating males. This work arises in the shadow of the contentious introduction of the HPV vaccine Gardasil (Merck & Co, Inc, Whitehouse Station, NJ) in 2006, particularly the opposition to efforts in many states to require the vaccine for school attendance. I review the current status of HPV vaccine policy in the United States and examine issues of public health ethics and policy central to ongoing and future HPV vaccination programs.
Schwartz
Jason L
JL
Center forBioethics and Department of History andSociology of Science, University ofPennsylvania, Philadelphia, PA 19104, USA. jlschwa2@mail.med.upenn.edu
D000293:Adolescent; D000328:Adult; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D003218:Condylomata Acuminata / Q000517:prevention & control*; D017277:Drug Approval; D005260:Female; D006291:Health Policy / Q000331:legislation & jurisprudence*; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D032541:Mass Vaccination / Q000331:legislation & jurisprudence*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000592:standards; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D055815:Young Adult
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18